BioCART
Research type
Research Study
Full title
An integrated multiomic and spectroscopic approach to the identification of new CAR-T biomarkers (BioCART) in blood using machine learning analysis
IRAS ID
340403
Contact name
Siang Boon Koh
Contact email
Sponsor organisation
University of Bristol
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Chimeric antigen receptor (CAR) T-cell therapy has revolutionised the outcome for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with reports of 40-60% complete remission in otherwise incurable patients. Despite these remarkable results the wider uptake of CART therapy is hindered by development of resistance and life-threatening toxicities such as cytokine release syndrome (CRS) and/or neurotoxicity. There is therefore a clear clinical need for biomarkers to efficiently monitor and manage the development of toxicities and disease progression.
Although several projects have used a transcriptomic/genomic approach to biomarker discovery in CART patients, either cellularly or in cell free DNA/RNA, to date these studies have used a single omic approach and nearly always with a small number of patients.
Our objective is to use a multi-omic techniques (including circulating tumour DNA, miRNA, methylomic, glycomic and spectroscopic) to identify novel blood based biomarkers in B-cell lymphoma patients treated with CART in a multi-centre international prospective study.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
24/PR/0829
Date of REC Opinion
16 Jul 2024
REC opinion
Favourable Opinion